The results from a cohort that included patients without diabetes, who were treated with IFNα for hepatitis C, showed that 143 out of 2,842 patients developed T2D during a mean observation time of 6.4 years. The gene discussed is IFNA1; the disease is type 2 diabetes mellitus.